Earnings ·
Liquidia reports $74.7M net income in Q2 as YUTREPIA sales rise 31% to $170.4M
LQDALiquidia Corp
Liquidia Corporation reported second quarter 2026 financial results on August 12, 2026. Net product sales for YUTREPIA reached approximately $170.4 million, a 31% increase from the first quarter of 2026. The company recorded net income of $74.7 million and adjusted EBITDA of $96.3 million, marking its fourth consecutive quarter of increasing profitability. Cash and cash equivalents totaled $284.2 million as of June 30, 2026. Since launching in June 2025, YUTREPIA has generated approximately 5,900 unique patient prescriptions and treated more than 5,000 patients. Liquidia Corporation is a biopharmaceutical company developing therapies for respiratory and vascular diseases using its proprietary PRINT technology.